Piper Jaffray Reiterates Overweight Rating On ABIOMED

According to Piper Jaffray, ABIOMED ABMD Overweight rating is reiterated. Piper Jaffray said that Abiomed delivered strong top line results for Q4:F11. “Revenue in the quarter totaled $28.5M (+24%), ahead of our $27.4M and consensus $27.7M estimates. GAAP EPS of ($0.05) was modestly below consensus of ($0.04) and PJC estimate of ($0.03). The company was cash flow positive for Q4, and expects to remain so through FY12. First time FY12 revenue guidance was for $120-$125M (+20-24%) vs consensus of $119M. We are raising our estimates and increasing our price target to $20/share. We reiterate our Overweight rating.” ABIOMED closed yesterday at $17.65.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsAbiomedHealth CareHealth Care EquipmentPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!